Therapie des malignen Aszites

  • H. Riess

Zusammenfassung

Bevorzugt bei Patienten mit fortgeschrittenen Stadien primär im abdominellen Raum lokalisierter Tumoren tritt im Verlauf bei bis zu 20 % — nahezu regelhaft bei Ovarialkarzinomen — maligner Aszites auf. Nur bei etwa der Hälfte dieser Patienten wird er klinisch manifest.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Garrison RN, Kaelin LD, Heusser LS et al. (1986) Malignant ascites. Ann Surg 203:644–651PubMedCrossRefGoogle Scholar
  2. 2.
    Myers CE (1985) The use of intraperitoneal chemotherapy. In: De Vitam VT, Hellman S, Rosenberg SA; Important Advances in Oncology, J.B. Lippincott Co: 218–225Google Scholar
  3. 3.
    Lifshitz S (1982) Ascites, pathophysiology and control measures. Int J Radiat Oncol Biol Phys 8:1423–1426PubMedCrossRefGoogle Scholar
  4. 4.
    Parsons SL, Watson SA, Steele RJC (1996) Malignant aszites. Br J Surg 83:6–14PubMedCrossRefGoogle Scholar
  5. 5.
    Cheung DK, Raaf JH (1982) Selection of patients with malignant ascites for a peritoneovenous shunt. Cancer 50:1204–1209PubMedCrossRefGoogle Scholar
  6. 6.
    Campioni N, Pasquali, Lasagni RP et al. (1986) Peritoneovenous shunt and neoplastic ascites: A 5 year experience report. J Surg Oncol 33:31–35PubMedCrossRefGoogle Scholar
  7. 7.
    Smith DAP, Weaver DW, Bouman DL (1989) Peritoneovenous shunts (PVS) for malignant ascites: An analysis of outcome. Am Surg 55:445–449PubMedGoogle Scholar
  8. 8.
    Jackson GL, Blosser NM (1981) Intracavitary chromic phosphate (32-P) colloidal suspension therapy. Cancer 48:2596–2598PubMedCrossRefGoogle Scholar
  9. 9.
    Rose RG (1962) Intracavitary radioactive colloidal gold: Result in 257 cancer patients. J Nucl Med 3:323–331PubMedGoogle Scholar
  10. 10.
    Markmann M (1991) Intraperitoneal chemotherapy. Semin Oncol 18:248–254Google Scholar
  11. 11.
    Piccart MJ, Speyer JL, Markman M et al. (1985) Intraperitoneal chemotherapy: Technical expirience at five institutions. Semin Oncol 12:90–96PubMedGoogle Scholar
  12. 12.
    Myers C (1985) The use of intraperitoneal chemotherapy in the treatment of ovarian cancer. Sem Oncol 12:275–284Google Scholar
  13. 13.
    Ostrowski MJ, Halsall GM (1982) Intracavitary bleomycin in the management of malignant effusions. Cancer Treat Rep 66:1903–1907PubMedGoogle Scholar
  14. 14.
    Reichmann B, Markman M, Hake T et al. (1989) Intraperitoneal cisplatin and etoposide in the treatment of refractory recurrent ovarian carcinoma. J Clin Oncol 7:1327–1332Google Scholar
  15. 15.
    Markman M, Cleary S, Lucas WE, Howell SB (1985) Intraperitoneal chemotherapy with high dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. J Clin Oncol 3:925–931PubMedGoogle Scholar
  16. 16.
    Alberts DS, Liu PY, Hannigan V et al. (1996) Intraperitoneal Cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 26:1950–1955CrossRefGoogle Scholar
  17. 17.
    Schwella N, Riess H, Lübbe AS, Salama ZB, Huhn D (1993) Intraperitoneal carbo-platin in the treatment of bulky disease ovarian cancer: experience in two cases. Onkologie 16:360–363CrossRefGoogle Scholar
  18. 18.
    Steis RG, Urba WJ, Vander Molan LA et al. (1990) Intraperitoneal lymphokine-activated killer cell and interleukin-2 therapy for malignancies limites to the peritoneal cavity. J Clin Oncol 8:1618–1629PubMedGoogle Scholar
  19. 19.
    Kober F, Heiss A, Roka R (1996) Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer 82:211–219Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • H. Riess

There are no affiliations available

Personalised recommendations